Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Year: 2013
Type: review
Abstract: Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatment-related side effects are frequent and full drug doses difficult to tolerate. We retrospectively analyzed data from 1435 elderly patients enrolled in 4 European phase III trials including thalidomide and/or bortezomib. After a median follow up of 33 months (95%CI: 10-56 months), 513 of 1435 patients (36%) died; median overall survival was 50 months (95%CI: 46-60 months). The risk of death was increased in patients aged 75 years or over (HR 1.44, 95%CI: 1.20-1.72; P<0.001), in patients with renal failure (HR 2.02, 95%CI: 1.51-2.70; P<0.001), in those who experienced grade 3-4 infections, cardiac or gastrointestinal adverse events during treatment (HR 2.53, 95%CI: 1.75-3.64; P<0.001) and in those who required drug discontinuation due to adverse events (HR 1.67, 95%CI; 1.12-2.51; P=0.01). This increased risk was restricted to the first six months after occurrence of adverse events or drug discontinuation and declined over time. More intensive approaches, such as the combination of bortezomib-thalidomide, negatively affected outcome. Bortezomib-based combinations may overcome the negative impact of renal failure. Age 75 years or over or renal failure at presentation, occurrence of infections, cardiac or gastrointestinal adverse events negatively affected survival. A detailed geriatric assessment, organ evaluation and less intense individualized approaches are suggested in elderly unfit subjects.
Source: Haematologica
Authors: S. Bringhen, M. V. Mateos, S. Zweegman, A. Larocca, A. P. Falcone, A. Oriol, D. Rossi, M. Cavalli, P. Wijermans, R. Ria, M. Offidani, J. J. Lahuerta, A. M. Liberati, R. Mina, V. Callea, M. Schaafsma, C. Cerrato, R. Marasca, L. Franceschini, A. Evangelista, A.-I. Teruel, B. van der Holt, V. Montefusco, G. Ciccone, M. Boccadoro, J. S. Miguel, P. Sonneveld, A. Palumbo
Institutions: Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Turin, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Amsterdam UMC Location Vrije Universiteit Amsterdam, Casa Sollievo della Sofferenza, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, University of Catania, Ferrarotto Hospital, Haga Hospital, University of Bari Aldo Moro, Azienda Ospedaliero-Universitaria delle Marche, Hospital Universitario 12 De Octubre, University of Perugia, Azienda ospedaliera "Bianchi-Melacrino-Morelli", Medisch Spectrum Twente, University of Modena and Reggio Emilia, Policlinico Tor Vergata, Piedmont Reference Center for Epidemiology and Cancer Prevention, Hospital Clínico Universitario de Valencia, Hovon, Erasmus MC Cancer Institute, Daniel den Hoed Kliniek, Fondazione IRCCS Istituto Nazionale dei Tumori
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2121558833
